2020 Encephalomyelitis Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Encephalomyelitis pipeline report presents a comprehensive overview of the research and development of Encephalomyelitis drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Five drugs in Pre-clinical phase, one drug in Phase 1 and two drugs in phase 2
As of February 2020, the Encephalomyelitis pipeline remains robust with 9 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Encephalomyelitis treatment. Diverse types of targeted therapies are being explored through clinical trials including Agammaglobulinaemia tyrosine kinase inhibitors; corticotropin-releasing factor receptor type 2 antagonist; dopamine transporter; noradrenaline transporter inhibitor; MDK protein inhibitors; NLRP3 inhibitor; Nuclear receptor subfamily 1 group F member 3 inverse agonists; Toll-like receptor 3 agonist; Immunomodulators.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Encephalomyelitis drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Encephalomyelitis pipeline drugs profiled in the report include- rintatolimod, AUR-101, Small Molecule for neurodegenerative disorders, CT38, MCC950, KPAX002, Evobrutinib, F8-IL4, RBM-001
As of February 2020, the Encephalomyelitis pipeline remains robust with 9 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Encephalomyelitis treatment. Diverse types of targeted therapies are being explored through clinical trials including Agammaglobulinaemia tyrosine kinase inhibitors; corticotropin-releasing factor receptor type 2 antagonist; dopamine transporter; noradrenaline transporter inhibitor; MDK protein inhibitors; NLRP3 inhibitor; Nuclear receptor subfamily 1 group F member 3 inverse agonists; Toll-like receptor 3 agonist; Immunomodulators.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Encephalomyelitis drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Encephalomyelitis development
- Encephalomyelitis pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Encephalomyelitis pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Encephalomyelitis pipeline candidates included
- Business overview and snapshot of all companies involved in Encephalomyelitis pipeline are included
- Latest market and pipeline developments are provided in the report
Encephalomyelitis pipeline drugs profiled in the report include- rintatolimod, AUR-101, Small Molecule for neurodegenerative disorders, CT38, MCC950, KPAX002, Evobrutinib, F8-IL4, RBM-001
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Encephalomyelitis Condition
2.3 Encephalomyelitis Pipeline Snapshot, 2020
2.4 Companies investing in Encephalomyelitis pipeline therapeutics
2.5 Phase wise Encephalomyelitis Pipeline Candidates
2.6 Most Researched Mechanism of Action of Encephalomyelitis Pipeline Products
2.7 Route of Administration of Encephalomyelitis Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 AIM ImmunoTech Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Aurigene Discovery Technologies Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 Biovista Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Cortene Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Inflazome Ltd Overview, Contacts and ASD Pipeline Drugs
3.6 K-Pax Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Merck Serono Overview, Contacts and ASD Pipeline Drugs
3.8 Philogen SpA Overview, Contacts and ASD Pipeline Drugs
3.9 Ribomic Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 rintatolimod Drug Details
4.1.1 rintatolimod Current Status
4.1.2 rintatolimod Drug Overview
4.1.3 rintatolimod Mechanism of Action
4.1.4 rintatolimod Licensing/Collaboration Companies
4.1.5 rintatolimod Clinical Trials
4.2 AUR-101 Drug Details
4.2.1 AUR-101 Current Status
4.2.2 AUR-101 Drug Overview
4.2.3 AUR-101 Mechanism of Action
4.2.4 AUR-101 Licensing/Collaboration Companies
4.2.5 AUR-101 Clinical Trials
4.3 Small Molecule for neurodegenerative disorders Drug Details
4.3.1 Small Molecule for neurodegenerative disorders Current Status
4.3.2 Small Molecule for neurodegenerative disorders Drug Overview
4.3.3 Small Molecule for neurodegenerative disorders Mechanism of Action
4.3.4 Small Molecule for neurodegenerative disorders Licensing/Collaboration Companies
4.3.5 Small Molecule for neurodegenerative disorders Clinical Trials
4.4 CT38 Drug Details
4.4.1 CT38 Current Status
4.4.2 CT38 Drug Overview
4.4.3 CT38 Mechanism of Action
4.4.4 CT38 Licensing/Collaboration Companies
4.4.5 CT38 Clinical Trials
4.5 MCC950 Drug Details
4.5.1 MCC950 Current Status
4.5.2 MCC950 Drug Overview
4.5.3 MCC950 Mechanism of Action
4.5.4 MCC950 Licensing/Collaboration Companies
4.5.5 MCC950 Clinical Trials
4.6 KPAX002 Drug Details
4.6.1 KPAX002 Current Status
4.6.2 KPAX002 Drug Overview
4.6.3 KPAX002 Mechanism of Action
4.6.4 KPAX002 Licensing/Collaboration Companies
4.6.5 KPAX002 Clinical Trials
4.7 Evobrutinib Drug Details
4.7.1 Evobrutinib Current Status
4.7.2 Evobrutinib Drug Overview
4.7.3 Evobrutinib Mechanism of Action
4.7.4 Evobrutinib Licensing/Collaboration Companies
4.7.5 Evobrutinib Clinical Trials
4.8 F8-IL4 Drug Details
4.8.1 F8-IL4 Current Status
4.8.2 F8-IL4 Drug Overview
4.8.3 F8-IL4 Mechanism of Action
4.8.4 F8-IL4 Licensing/Collaboration Companies
4.8.5 F8-IL4 Clinical Trials
4.9 RBM-001 Drug Details
4.9.1 RBM-001 Current Status
4.9.2 RBM-001 Drug Overview
4.9.3 RBM-001 Mechanism of Action
4.9.4 RBM-001 Licensing/Collaboration Companies
4.9.5 RBM-001 Clinical Trials
5. LATEST ENCEPHALOMYELITIS PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Encephalomyelitis Condition
2.3 Encephalomyelitis Pipeline Snapshot, 2020
2.4 Companies investing in Encephalomyelitis pipeline therapeutics
2.5 Phase wise Encephalomyelitis Pipeline Candidates
2.6 Most Researched Mechanism of Action of Encephalomyelitis Pipeline Products
2.7 Route of Administration of Encephalomyelitis Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 AIM ImmunoTech Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Aurigene Discovery Technologies Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 Biovista Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Cortene Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Inflazome Ltd Overview, Contacts and ASD Pipeline Drugs
3.6 K-Pax Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Merck Serono Overview, Contacts and ASD Pipeline Drugs
3.8 Philogen SpA Overview, Contacts and ASD Pipeline Drugs
3.9 Ribomic Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 rintatolimod Drug Details
4.1.1 rintatolimod Current Status
4.1.2 rintatolimod Drug Overview
4.1.3 rintatolimod Mechanism of Action
4.1.4 rintatolimod Licensing/Collaboration Companies
4.1.5 rintatolimod Clinical Trials
4.2 AUR-101 Drug Details
4.2.1 AUR-101 Current Status
4.2.2 AUR-101 Drug Overview
4.2.3 AUR-101 Mechanism of Action
4.2.4 AUR-101 Licensing/Collaboration Companies
4.2.5 AUR-101 Clinical Trials
4.3 Small Molecule for neurodegenerative disorders Drug Details
4.3.1 Small Molecule for neurodegenerative disorders Current Status
4.3.2 Small Molecule for neurodegenerative disorders Drug Overview
4.3.3 Small Molecule for neurodegenerative disorders Mechanism of Action
4.3.4 Small Molecule for neurodegenerative disorders Licensing/Collaboration Companies
4.3.5 Small Molecule for neurodegenerative disorders Clinical Trials
4.4 CT38 Drug Details
4.4.1 CT38 Current Status
4.4.2 CT38 Drug Overview
4.4.3 CT38 Mechanism of Action
4.4.4 CT38 Licensing/Collaboration Companies
4.4.5 CT38 Clinical Trials
4.5 MCC950 Drug Details
4.5.1 MCC950 Current Status
4.5.2 MCC950 Drug Overview
4.5.3 MCC950 Mechanism of Action
4.5.4 MCC950 Licensing/Collaboration Companies
4.5.5 MCC950 Clinical Trials
4.6 KPAX002 Drug Details
4.6.1 KPAX002 Current Status
4.6.2 KPAX002 Drug Overview
4.6.3 KPAX002 Mechanism of Action
4.6.4 KPAX002 Licensing/Collaboration Companies
4.6.5 KPAX002 Clinical Trials
4.7 Evobrutinib Drug Details
4.7.1 Evobrutinib Current Status
4.7.2 Evobrutinib Drug Overview
4.7.3 Evobrutinib Mechanism of Action
4.7.4 Evobrutinib Licensing/Collaboration Companies
4.7.5 Evobrutinib Clinical Trials
4.8 F8-IL4 Drug Details
4.8.1 F8-IL4 Current Status
4.8.2 F8-IL4 Drug Overview
4.8.3 F8-IL4 Mechanism of Action
4.8.4 F8-IL4 Licensing/Collaboration Companies
4.8.5 F8-IL4 Clinical Trials
4.9 RBM-001 Drug Details
4.9.1 RBM-001 Current Status
4.9.2 RBM-001 Drug Overview
4.9.3 RBM-001 Mechanism of Action
4.9.4 RBM-001 Licensing/Collaboration Companies
4.9.5 RBM-001 Clinical Trials
5. LATEST ENCEPHALOMYELITIS PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
